BioMarin Pharmaceutical Inc. (BMRN)

90,74 +0,63 (+0,70%) Alla chiusura: 04:00PM EDT

BioMarin Pharmaceutical Inc.

770 Lindaro Street
San Rafael, CA 94901
United States
415 506 6700
https://www.biomarin.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 3.082

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Jean-Jacques Bienaime M.B.A., MBA	Chairman & CEO	3,67M	8,16M	1953
Mr. Brian R. Mueller	Exec. VP of Fin. & CFO	1,13M	343,97k	1974
Dr. C. Greg Guyer Ph.D.	CTO and Exec. VP of Global Manufacturing & Technical Operations	1,75M	N/D	1962
Mr. Jeffrey Robert Ajer	Exec. VP & Chief Commercial Officer	1,2M	N/D	1962
Dr. Henry J. Fuchs M.D., Ph.D.	Pres of Worldwide R&D	1,52M	N/D	1958
Ms. Erin Burkhart	Group VP & Chief Accounting Officer	N/D	N/D	N/D
Traci McCarty	VP of Investor Relations	N/D	N/D	N/D
Mr. George Eric Davis	Exec. VP & Chief Legal Officer	N/D	N/D	1971
Mr. Philip Lo Scalzo	Sr. VP & Chief Compliance Officer	N/D	N/D	N/D
Ms. Humaira Serajuddin	Sr. VP & Chief Marketing Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Governance aziendale

L'ISS Governance QualityScore di BioMarin Pharmaceutical Inc. al 1 marzo 2023 è 6. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 4; diritti degli azionisti: 5; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.